Cargando…
PET/CT-Based Salvage Radiotherapy for Recurrent Prostate Cancer After Radical Prostatectomy: Impact on Treatment Management and Future Directions
Biochemical recurrence is a clinical situation experienced by 20 to 40% of prostate cancer patients treated with radical prostatectomy (RP). Prostate bed (PB) radiation therapy (RT) remains the mainstay salvage treatment, although it remains non-curative for up to 30% of patients developing further...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8438304/ https://www.ncbi.nlm.nih.gov/pubmed/34532294 http://dx.doi.org/10.3389/fonc.2021.742093 |
_version_ | 1783752342628204544 |
---|---|
author | le Guevelou, Jennifer Achard, Vérane Mainta, Ismini Zaidi, Habib Garibotto, Valentina Latorzeff, Igor Sargos, Paul Ménard, Cynthia Zilli, Thomas |
author_facet | le Guevelou, Jennifer Achard, Vérane Mainta, Ismini Zaidi, Habib Garibotto, Valentina Latorzeff, Igor Sargos, Paul Ménard, Cynthia Zilli, Thomas |
author_sort | le Guevelou, Jennifer |
collection | PubMed |
description | Biochemical recurrence is a clinical situation experienced by 20 to 40% of prostate cancer patients treated with radical prostatectomy (RP). Prostate bed (PB) radiation therapy (RT) remains the mainstay salvage treatment, although it remains non-curative for up to 30% of patients developing further recurrence. Positron emission tomography with computed tomography (PET/CT) using prostate cancer-targeting radiotracers has emerged in the last decade as a new-generation imaging technique characterized by a better restaging accuracy compared to conventional imaging. By adapting targeting of recurrence sites and modulating treatment management, implementation in clinical practice of restaging PET/CT is challenging the established therapeutic standards born from randomized controlled trials. This article reviews the potential impact of restaging PET/CT on changes in the management of recurrent prostate cancer after RP. Based on PET/CT findings, it addresses potential adaptation of RT target volumes and doses, as well as use of androgen-deprivation therapy (ADT). However, the impact of such management changes on the oncological outcomes of PET/CT-based salvage RT strategies is as yet unknown. |
format | Online Article Text |
id | pubmed-8438304 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-84383042021-09-15 PET/CT-Based Salvage Radiotherapy for Recurrent Prostate Cancer After Radical Prostatectomy: Impact on Treatment Management and Future Directions le Guevelou, Jennifer Achard, Vérane Mainta, Ismini Zaidi, Habib Garibotto, Valentina Latorzeff, Igor Sargos, Paul Ménard, Cynthia Zilli, Thomas Front Oncol Oncology Biochemical recurrence is a clinical situation experienced by 20 to 40% of prostate cancer patients treated with radical prostatectomy (RP). Prostate bed (PB) radiation therapy (RT) remains the mainstay salvage treatment, although it remains non-curative for up to 30% of patients developing further recurrence. Positron emission tomography with computed tomography (PET/CT) using prostate cancer-targeting radiotracers has emerged in the last decade as a new-generation imaging technique characterized by a better restaging accuracy compared to conventional imaging. By adapting targeting of recurrence sites and modulating treatment management, implementation in clinical practice of restaging PET/CT is challenging the established therapeutic standards born from randomized controlled trials. This article reviews the potential impact of restaging PET/CT on changes in the management of recurrent prostate cancer after RP. Based on PET/CT findings, it addresses potential adaptation of RT target volumes and doses, as well as use of androgen-deprivation therapy (ADT). However, the impact of such management changes on the oncological outcomes of PET/CT-based salvage RT strategies is as yet unknown. Frontiers Media S.A. 2021-08-31 /pmc/articles/PMC8438304/ /pubmed/34532294 http://dx.doi.org/10.3389/fonc.2021.742093 Text en Copyright © 2021 le Guevelou, Achard, Mainta, Zaidi, Garibotto, Latorzeff, Sargos, Ménard and Zilli https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Oncology le Guevelou, Jennifer Achard, Vérane Mainta, Ismini Zaidi, Habib Garibotto, Valentina Latorzeff, Igor Sargos, Paul Ménard, Cynthia Zilli, Thomas PET/CT-Based Salvage Radiotherapy for Recurrent Prostate Cancer After Radical Prostatectomy: Impact on Treatment Management and Future Directions |
title | PET/CT-Based Salvage Radiotherapy for Recurrent Prostate Cancer After Radical Prostatectomy: Impact on Treatment Management and Future Directions |
title_full | PET/CT-Based Salvage Radiotherapy for Recurrent Prostate Cancer After Radical Prostatectomy: Impact on Treatment Management and Future Directions |
title_fullStr | PET/CT-Based Salvage Radiotherapy for Recurrent Prostate Cancer After Radical Prostatectomy: Impact on Treatment Management and Future Directions |
title_full_unstemmed | PET/CT-Based Salvage Radiotherapy for Recurrent Prostate Cancer After Radical Prostatectomy: Impact on Treatment Management and Future Directions |
title_short | PET/CT-Based Salvage Radiotherapy for Recurrent Prostate Cancer After Radical Prostatectomy: Impact on Treatment Management and Future Directions |
title_sort | pet/ct-based salvage radiotherapy for recurrent prostate cancer after radical prostatectomy: impact on treatment management and future directions |
topic | Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8438304/ https://www.ncbi.nlm.nih.gov/pubmed/34532294 http://dx.doi.org/10.3389/fonc.2021.742093 |
work_keys_str_mv | AT legueveloujennifer petctbasedsalvageradiotherapyforrecurrentprostatecancerafterradicalprostatectomyimpactontreatmentmanagementandfuturedirections AT achardverane petctbasedsalvageradiotherapyforrecurrentprostatecancerafterradicalprostatectomyimpactontreatmentmanagementandfuturedirections AT maintaismini petctbasedsalvageradiotherapyforrecurrentprostatecancerafterradicalprostatectomyimpactontreatmentmanagementandfuturedirections AT zaidihabib petctbasedsalvageradiotherapyforrecurrentprostatecancerafterradicalprostatectomyimpactontreatmentmanagementandfuturedirections AT garibottovalentina petctbasedsalvageradiotherapyforrecurrentprostatecancerafterradicalprostatectomyimpactontreatmentmanagementandfuturedirections AT latorzeffigor petctbasedsalvageradiotherapyforrecurrentprostatecancerafterradicalprostatectomyimpactontreatmentmanagementandfuturedirections AT sargospaul petctbasedsalvageradiotherapyforrecurrentprostatecancerafterradicalprostatectomyimpactontreatmentmanagementandfuturedirections AT menardcynthia petctbasedsalvageradiotherapyforrecurrentprostatecancerafterradicalprostatectomyimpactontreatmentmanagementandfuturedirections AT zillithomas petctbasedsalvageradiotherapyforrecurrentprostatecancerafterradicalprostatectomyimpactontreatmentmanagementandfuturedirections |